Figure 5: Combination therapy with SVF and Ad-COMP-Ang1 gene restores claudin-5 expression in STZ-induced diabetic mice. (a) CD31 (green) and Claudin-5 (red) staining in cavernous tissue from age-matched control mice (C) group and STZ-induced diabetic mice stimulated at 4 weeks after intracavernous injection of PBS (P, 20 μl), ad-LacZ (L, 2 × 108 particles per 20 μl), SVF (S, 1 × 105 cells per 20 μl), Ad-COMP-Ang1 (CA, 2 × 108 particles per 20 μl), or combination (S + CA). Nuclei were labeled with DAPI (blue). Scale bars=100 μm. (b) Representative western blots and (c) relative ratio for claudin-5 in the mouse penis compared with that of β-actin. Each bar depicts the mean value ± standard deviation from n = 4 animals per group. *P < 0.001, P or L versus C group. #P < 0.05, S or CA versus P or L groups. †P < 0.05, S + CA versus S or CA groups. (d) Quantification of the claudin-5 immunopositive area in cavernous tissue by ImageJ. Each bar depicts the mean values ± standard deviations from n = 5 animals per group. *P < 0.001, P or L versus C group. #P < 0.05, S or CA versus P or L groups. †P < 0.01, S + CA versus S or CA groups. The P values were determined by one-way ANOVA. Ad-COMP-Ang1: adenovirus-mediated cartilage oligomeric matrix angiopoietin-1; DAPI: 4',6-diamidino-2-phenylindole; PBS: phosphate-buffered saline; STZ: streptozotocin; SVF: stromal vascular fraction.